Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Inhibition of C3 with APL-2 Results in Normalisation of Markers of Intravascular and Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Raymond SM Wong, MRCP, FRCP, Humphrey W.H. Pullon, FRACP, FRCPA, Pascal Deschatelets, PhD, Cedric G Francois, MD PhD, Mohamed Hamdani, MS, Surapol Issaragrisil, MD, Patrick Johnson, PhD, Pimjai Niparuck, MD, Tontanai Numbenjapon, MD, Jameela Sathar, MB, MRCP, MRCPath, Lisa Tan, Eric Tse, MBBS, PhD FRCP, FRCPath, Federico Grossi, MD

Blood (2018) 132 (Supplement 1): 2314.

https://doi.org/10.1182/blood-2018-99-110827

Published: 2018

Journal Articles

APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers

Federico V Grossi, MDPhD, Pauline Bedwell, Pascal Deschatelets, PhD, Lil Edis, PhD, Cedric G Francois, MDPhD, Patrick J Johnson, PhD, Helen J Richardson, Lisa Tan, Carolina A Vega, Jason Lickliter, MBBS,PhD

Blood (2016) 128 (22): 1251.

https://doi.org/10.1182/blood.V128.22.1251.1251

Published: 2016

Journal Articles

Preclinical Evaluation of RA101495, a Potent Cyclic Peptide Inhibitor of C5 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Alonso Ricardo, PhD, Michelle Arata, MS, Steven DeMarco, PhD, Ketki Dhamnaskar, MS, Robert Hammer, PhD, Masha Fridkis-Hareli, PhD, Vaishnavi Rajagopal, PhD, Kathleen Seyb, PhD, Guo-Qing Tang, PhD, Sylvia Tobe, PhD, Douglas Treco, PhD

Blood (2015) 126 (23): 939.

https://doi.org/10.1182/blood.V126.23.939.939

Published: 2015

Journal Articles

Development of RA101348, a Potent Cyclic Peptide Inhibitor of C5 for Complement-Mediated Diseases

Alonso Ricardo, PhD, Michelle Arata, Steven J DeMarco, PhD, Ketki Dhamnaskar, Robert Hammer, PhD, Kristopher Josephson, PhD, Kathleen Seyb, PhD, Sylvia Tobe, PhD, Zhaolin Wang, PhD, Hong Zheng, PhD, Douglas Treco, PhD

Blood (2014) 124 (21): 2936.

https://doi.org/10.1182/blood.V124.21.2936.2936

Published: 2014

Journal Articles

A TFPI Inhibitory Half Life Extended Fusion Peptide Proves Efficacy in FVIII Knock out Mice and Marmoset Monkeys

Michael Dockal, PhD, Rudolf Hartmann, PhD, Thomas Polakowski, PhD, Erwin Panholzer, Willibald Kammlander, Frank Osterkamp, PhD, Ulrich Reineke, PhD, Alexandra Schiviz, PhD, Werner Hoellriegl, PhD, Friedrich Scheiflinger, PhD

Blood (2014) 124 (21): 1469.

https://doi.org/10.1182/blood.V124.21.1469.1469

Published: 2014

Journal Articles

A Novel C5 Complement Inhibitor Protects Against Sepsis-Induced Activation of Complement, Coagulation and Inflammation and Provides Survival Benefit in E. coli Sepsis

Ravi Keshari, PhD, Robert Silasi-Mansat, PhD, Narcis I. Popescu, PhD, Hala Chaaban, MD, Cristina Lupu, PhD, Steven J DeMarco, PhD, Florea Lupu, PhD

Blood (2014) 124 (21): 112.

https://doi.org/10.1182/blood.V124.21.112.112

Published: 2014

Journal Articles

Molecular Characterization of the Synergistic Effect on TFPI Inhibition By Fusion of Two Inhibitory Peptides

Michael Dockal, PhD, Rudolf Hartmann, PhD, Thomas Polakowski, PhD, Christoph Redl, Erwin Panholzer, Willibald Kammlander, Frank Osterkamp, PhD, Ulrich Reineke, PhD, Hans Brandstetter, Prof., Friedrich Scheiflinger, PhD

Blood (2014) 124 (21): 1484.

https://doi.org/10.1182/blood.V124.21.1484.1484

Published: 2014

Journal Articles

“Red Cell Complement Loading In PNH Patients On Eculizumab Is Associated With a C3 Polymorphism Which Influences C3 Function, Predicts For Increased Extravascular Hemolysis and Provides a Rationale For C3 Inhibition.”

Praveen Kaudlay, MBBS, MRCP, Haiying Hua, MD, Guansheng He, MD, Darren J Newton, PhD, Abraham M Varghese, MB ChB, Talha Munir, MBBS, MRCP, FRCPath, Anita Hill, MBChB, PhD, Richard J Kelly, MBChB, Stephen John Richards, PhD, Peter Hillmen, MB ChB, PhD

Blood (2013) 122 (21): 2466.

https://doi.org/10.1182/blood.V122.21.2466.2466

Published: 2013

Journal Articles

Human and Murine β-Defensin-Derived Peptides Induce Rapid Mobilization Of Murine Hematopoietic Stem and Progenitor Cells Via Activation Of CXCR4 Signaling and CXCL12 Release

Amir Schajnovitz, PhD, Alexander Kalinkovich, MD, PhD, Kfir Lapid, PhD, Alexander Berchanski, PhD, Tomer Itkin, PhD, Aya Ludin, DMD, PhD, Shiri Gur-Cohen, MSc, Karin Golan, MSc, Borja Saez, PhD, Orit Kollet, PhD, Kerstin Ahrens, PhD, Ehrahrdt Proksch, MD, PhD, Aviva Lapidot, PhD, Matityahu Fridkin, PhD, David T. Scadden, MD, Tsvee Lapidot, PhD

Blood (2013) 122 (21): 890.

https://doi.org/10.1182/blood.V122.21.890.890

Published: 2013

Journal Articles

Crystal Structure Of Tissue Factor Pathway Inhibitor (TFPI) Kunitz Domain 1 and 2 In Complex With An Inhibitory Cyclic Peptide,

Michael Dockal, PhD, Rudolf Hartmann, PhD, Markus Fries, PhD, Katerina Prohaska, Robert Pachlinger, PhD, Thomas Polakowski, PhD, Johannes Brandstetter, PhD, Jan Rosing, PhD, Friedrich Scheiflinger, PhD

Blood (2013) 122 (21): 453.

https://doi.org/10.1182/blood.V122.21.453.453

Published: 2013

Journal Articles

Adhesion of Hairy Cells Leukemia (HCL) Cells to Stromal Cells Can Be Inhibited by Blocking VLA-4 Integrins and CXCR4 Chemokine Receptors

Mariela Sivina, PhD, Robert J. Kreitman, MD, Amnon Peled, PhD, Farhad Ravandi, MD, Jan A. Burger, MD, PhD

Blood (2011) 118 (21): 1760.

https://doi.org/10.1182/blood.V118.21.1760.1760

Published: 2011

Journal Articles

Screening Small Molecule Inhibitors of VLA-5 to Block the Interaction Between Acute Lymphoblastic Leukemia with Ph+ and Their Microenvironment.

Zhongbo Hu, MD, PhD, Xiaomiao Li, PhD, David Ostrov, PhD, William Slayton, MD

Blood (2010) 116 (21): 1027.

https://doi.org/10.1182/blood.V116.21.1027.1027

Published: 2010

Journal Articles

Glycoprotein Ibα inhibitor complex structure reveals a combined steric and allosteric mechanism of von Willebrand factor antagonism

Paul A. McEwan, Robert K. Andrews, Jonas Emsley

Blood (2009) 114 (23): 4883–4885.

https://doi.org/10.1182/blood-2009-05-224170

Published: 2009

Includes: Multimedia, Supplemental data

Journal Articles

Largazole, a Novel Cyclic Peptide Histone Deacetylase Inhibitor, Demonstrates Anti-MM Effects Alone and Increases the Anti-MM Effects of Bortezomib.

Zhi-Wei Li, PhD, Mengyin Hu, Crystal Leung, Jeffrey A Steinberg, Jing Shen, Mingjie Li, Cathy S Wang, Eric Sanchez, Albert Bowers, Thomas Greshock, Kenneth Miller, Tenaya Newkirk, Nathan West, James E. Bradner, MD, Robert M Williams, PhD, Benjamin Bonavida, PhD, Haiming Chen, MD, PhD, James R. Berenson, MD

Blood (2009) 114 (22): 4925.

https://doi.org/10.1182/blood.V114.22.4925.4925

Published: 2009

Journal Articles

CC102528: A Novel Histone Deacetylase Inhibitor in the Hydroxamate Family Demonstrates Potent Anti-Myeloma Activity.

Zhi-Wei Li, PhD, Crystal Leung, Mengyin Hu, Jinbao Xiang, Chao Jiang, Jeffrey A Steinberg, Jing Shen, Mingjie Li, Cathy S Wang, Eric Sanchez, Benjamin Bonavida, PhD, Haiming Chen, MD, PhD, Xu Bai, James R. Berenson, MD

Blood (2009) 114 (22): 4927.

https://doi.org/10.1182/blood.V114.22.4927.4927

Published: 2009

Journal Articles

NGR and isoDGR are separate moieties binding to different receptors

Gian-Paolo Rizzardi, Claudio Bordignon

Blood (2009) 113 (21): 5366.

https://doi.org/10.1182/blood-2009-02-207068

Published: 2009

Journal Articles

Migratory Activity and Stromal Cell Adhesion of Mantle Cell Lymphoma Cells Can Be Diminished by Blocking of VLA-4 and CXCR4 Receptors

Antonina Kurtova, MS, Archie Tamayo, Richard J. Ford, Jr., MD, PhD, Jan A. Burger, MD, PhD

Blood (2008) 112 (11): 2825.

https://doi.org/10.1182/blood.V112.11.2825.2825

Published: 2008

Journal Articles

Identification and Characterization of a Human Platelet Glycoprotein VI Peptidomimetic Permitting Molecular Imaging of Fibrosis.

Martine Jandrot-Perrus, Julien Muzard, Laure Sarda-Mantel, Stéphane Loyau, Alain Meulemans, Liliane Louedec, Florence Hervatin, Jean-Baptiste Michel, Dominique Le Guludec, Philippe Billiald

Blood (2008) 112 (11): 1830.

https://doi.org/10.1182/blood.V112.11.1830.1830

Published: 2008

Journal Articles

Combined Tissue Factor Pathway Inhibitor (TFPI) and Thrombomodulin (TM) Deficiency Produces an Augmented Hypercoagulable State with Tissue Specific Fibrin Deposition.

Susan A. Maroney, DVM, PhD, Brian C. Cooley, PhD, Rashmi Sood, PhD, Hartmut Weiler, PhD, Alan E. Mast, MD PhD

Blood (2007) 110 (11): 265.

https://doi.org/10.1182/blood.V110.11.265.265

Published: 2007

Journal Articles

Functional and Computational Analysis of the Role of the Adjacent to Metal Ion-Dependent Adhesion Site (ADMIDAS) of Integrin αIIbβ3.

Marketa Jirouskova, PhD, Marta Murcia, PhD, JiHong Li, MD, Marta Filizola, PhD, Barry S. Coller, MD

Blood (2006) 108 (11): 143.

https://doi.org/10.1182/blood.V108.11.143.143

Published: 2006

NARROW

Inhibition of C3 with APL-2 Results in Normalisation of Markers of Intravascular and Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers

Preclinical Evaluation of RA101495, a Potent Cyclic Peptide Inhibitor of C5 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Development of RA101348, a Potent Cyclic Peptide Inhibitor of C5 for Complement-Mediated Diseases

A TFPI Inhibitory Half Life Extended Fusion Peptide Proves Efficacy in FVIII Knock out Mice and Marmoset Monkeys

A Novel C5 Complement Inhibitor Protects Against Sepsis-Induced Activation of Complement, Coagulation and Inflammation and Provides Survival Benefit in E. coli Sepsis

Molecular Characterization of the Synergistic Effect on TFPI Inhibition By Fusion of Two Inhibitory Peptides

“Red Cell Complement Loading In PNH Patients On Eculizumab Is Associated With a C3 Polymorphism Which Influences C3 Function, Predicts For Increased Extravascular Hemolysis and Provides a Rationale For C3 Inhibition.”

Human and Murine β-Defensin-Derived Peptides Induce Rapid Mobilization Of Murine Hematopoietic Stem and Progenitor Cells Via Activation Of CXCR4 Signaling and CXCL12 Release

Crystal Structure Of Tissue Factor Pathway Inhibitor (TFPI) Kunitz Domain 1 and 2 In Complex With An Inhibitory Cyclic Peptide,

Adhesion of Hairy Cells Leukemia (HCL) Cells to Stromal Cells Can Be Inhibited by Blocking VLA-4 Integrins and CXCR4 Chemokine Receptors

Screening Small Molecule Inhibitors of VLA-5 to Block the Interaction Between Acute Lymphoblastic Leukemia with Ph+ and Their Microenvironment.

Glycoprotein Ibα inhibitor complex structure reveals a combined steric and allosteric mechanism of von Willebrand factor antagonism

Largazole, a Novel Cyclic Peptide Histone Deacetylase Inhibitor, Demonstrates Anti-MM Effects Alone and Increases the Anti-MM Effects of Bortezomib.

CC102528: A Novel Histone Deacetylase Inhibitor in the Hydroxamate Family Demonstrates Potent Anti-Myeloma Activity.

NGR and isoDGR are separate moieties binding to different receptors

Migratory Activity and Stromal Cell Adhesion of Mantle Cell Lymphoma Cells Can Be Diminished by Blocking of VLA-4 and CXCR4 Receptors

Identification and Characterization of a Human Platelet Glycoprotein VI Peptidomimetic Permitting Molecular Imaging of Fibrosis.

Combined Tissue Factor Pathway Inhibitor (TFPI) and Thrombomodulin (TM) Deficiency Produces an Augmented Hypercoagulable State with Tissue Specific Fibrin Deposition.

Functional and Computational Analysis of the Role of the Adjacent to Metal Ion-Dependent Adhesion Site (ADMIDAS) of Integrin αIIbβ3.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only